Litigation Details for Novartis Pharmaceuticals Corporation v. Crystal Pharmaceutical (Suzhou) Co., Ltd. (D. Del. 2021)

Novartis Pharmaceuticals Corporation v. Crystal Pharmaceutical (Suzhou) Co., Ltd. (D. Del. 2021)

Docket		Date Filed	2021-10-14
Court	District Court, D. Delaware	Date Terminated	2023-05-30
Cause	35:271 Patent Infringement	Assigned To	Richard Gibson Andrews
Jury Demand	None	Referred To
Patents	11,058,667; 11,135,192; 9,517,226; 9,937,143
Link to Docket	External link to docket

Details for Novartis Pharmaceuticals Corporation v. Crystal Pharmaceutical (Suzhou) Co., Ltd. (D. Del. 2021)

Date Filed	Document No.	Description	Snippet	Link To Document
2021-10-14				External link to document

Novartis v. Crystal Pharmaceutical Patent Litigation: Entresto ANDA Case No. 1:21-cv-01452

Last updated: August 5, 2026

Novartis Pharmaceuticals Corporation sued Crystal Pharmaceutical (Suzhou) Co., Ltd. in the U.S. District Court for the District of Delaware after Crystal submitted an abbreviated new drug application seeking approval for a generic version of Entresto, Novartis’ sacubitril/valsartan product. The case was an ANDA Paragraph IV patent dispute, not a biosimilar proceeding. Novartis asserted Entresto-related patents covering the sacubitril/valsartan combination, pharmaceutical compositions, dosage forms, and therapeutic use.[1]

The case was assigned to Judge Richard G. Andrews under Case No. 1:21-cv-01452-RGA. The docket reflects resolution without a reported merits trial or final invalidity ruling. The commercial significance was the timing and conditions of potential generic entry into the U.S. heart-failure market.

What drug and regulatory pathway were at issue in Novartis v. Crystal?

Crystal’s ANDA targeted Entresto, which contains sacubitril and valsartan in a fixed-dose combination. Entresto is approved for heart-failure indications and is regulated under the FDA’s ANDA pathway because a proposed generic can rely on the reference listed drug’s safety and efficacy findings.[2]

Crystal’s filing apparently included Paragraph IV certifications against Orange Book-listed patents. A Paragraph IV certification asserts that a listed patent is invalid, unenforceable, or would not be infringed by the proposed generic. Novartis’ complaint followed the statutory 45-day period after receipt of Crystal’s Paragraph IV notice.[3]

Item	Case detail
Reference product	Entresto
Active ingredients	Sacubitril and valsartan
Regulatory pathway	ANDA under Section 505(j) of the Federal Food, Drug, and Cosmetic Act
Challenger	Crystal Pharmaceutical (Suzhou) Co., Ltd.
Patent holder and plaintiff	Novartis Pharmaceuticals Corporation
Court	U.S. District Court for the District of Delaware
Case number	1:21-cv-01452-RGA
Case type	Hatch-Waxman Paragraph IV litigation
Biologic issue	None; Entresto is a small-molecule combination product

What patents did Novartis assert against Crystal?

Novartis’ Entresto patent estate included patents directed to the combination of sacubitril and valsartan, composition characteristics, pharmaceutical formulations, and treatment methods. The asserted portfolio in this case included the following U.S. patents identified in the complaint and related Orange Book materials:[1,4]

U.S. patent	General patent-estate role	Relevance to generic entry
8,101,659	Sacubitril/valsartan combination and pharmaceutical composition claims	Core combination-product protection
8,404,744	Combination composition claims	Overlapping protection for the active ingredients
8,872,036	Sacubitril/valsartan pharmaceutical composition claims	Composition and formulation coverage
9,388,134	Combination-product claims	Additional composition protection
9,517,226	Pharmaceutical composition claims	Layered protection around Entresto
10,300,074	Later-issued composition or formulation claims	Follow-on protection
10,925,838	Later-issued Entresto-related claims	Additional patent barrier depending on the ANDA’s proposed labeling and formulation

The patents were not equivalent in litigation value. Core composition patents generally create the broadest infringement theories because they can read directly on the generic product. Method-of-use patents can be narrower because infringement may depend on the proposed label, physician use, or induced-infringement theories. Formulation patents can be important where the ANDA uses the same dosage-form architecture, excipients, release characteristics, or solid-state properties as the reference product.

The precise scope of risk depended on Crystal’s ANDA formulation, proposed labeling, Paragraph IV notice, and any section-viii carve-outs. A generic applicant may attempt to omit a patented indication from its label, but that strategy does not eliminate risk if the remaining label still encourages the patented use.

When does Entresto lose U.S. patent exclusivity?

Entresto’s exclusivity timeline is divided between regulatory exclusivity and patent protection. FDA regulatory exclusivity and patent expiration are separate concepts.

Protection	Significance
New chemical entity exclusivity	Initially prevented ANDA submission for the statutory period
Pediatric exclusivity	Can add six months to applicable exclusivity or patent terms
Orange Book patents	Can trigger a 30-month stay after a timely Paragraph IV suit
Patent-term adjustment or extension	Can move the effective barrier beyond the basic 20-year term
Method-of-use patents	Can restrict approval or create infringement exposure based on labeling

The earliest foundational Entresto patents had nominal terms tied to the underlying priority filings, but the effective U.S. market-exclusivity analysis must account for patent-term adjustment, patent-term extension, pediatric exclusivity, terminal disclaimers, and any later-issued continuation patents. FDA’s Orange Book remains the controlling public source for listed patent expiration information and pediatric exclusivity codes.[4]

Novartis’ commercial disclosures have historically treated Entresto’s U.S. patent protection as extending into the middle of the decade rather than ending when the earliest basic composition patent reached its unadjusted term.[5] Crystal’s ANDA litigation therefore addressed a period in which early generic approval could have materially affected Entresto revenue.

Did Crystal file a Paragraph IV challenge?

Yes. The litigation structure indicates that Crystal submitted an ANDA containing Paragraph IV certifications against Entresto-related Orange Book patents. Novartis then filed suit within the statutory 45-day period.

A Paragraph IV lawsuit generally triggers a 30-month statutory stay of FDA approval, subject to early termination or court action. The stay is a regulatory delay mechanism, not a determination that the patents are valid or infringed. The court must still resolve infringement, validity, and enforceability issues unless the parties settle before judgment.[3]

The important commercial point is that an ANDA filing can establish a first meaningful generic-entry date even when the litigation ends through settlement. The applicant may receive a license to launch on an agreed date, subject to conditions such as court approval, patent expiration, other generic settlements, or regulatory approval.

What formulation and method-of-use issues affected the case?

Entresto litigation has several potential claim categories.

Combination and composition claims

Claims directed to the combined use or composition of sacubitril and valsartan are generally the strongest barriers when the ANDA uses the same active ingredients in materially similar amounts. These claims can create direct infringement theories based on the manufacture, importation, offer for sale, or sale of the ANDA product.

Formulation claims

Formulation claims may cover tablet composition, excipients, dosage strengths, physical properties, or other pharmaceutical-technology elements. Crystal’s risk would depend on whether its proposed tablets used the claimed formulation features and whether the relevant claims survived validity challenges.

Method-of-use claims

Method claims can cover treating heart failure, reducing cardiovascular mortality, or related clinical outcomes. The FDA-approved label is central. If Crystal carved out a patented indication, Novartis could still argue that the remaining label, product design, promotional conduct, or predictable physician use induced infringement.

Manufacturing and solid-state claims

Later-issued patents may create manufacturing or product-by-process barriers. These claims can be difficult to assess from public information because the applicant’s detailed manufacturing process and batch specifications are generally protected from public disclosure. A generic applicant may avoid some process claims through a different manufacturing route, but composition claims can remain independently enforceable.

What was the litigation status and outcome?

The public docket does not reflect a reported trial verdict, claim-construction judgment, or final merits decision holding the asserted patents invalid or not infringed. The case was resolved through a negotiated disposition and closed without a judicial merits determination.[1]

That outcome limits the precedential value of the case. It does not establish that Crystal’s ANDA infringed the patents, nor does it establish that Novartis’ patents would have survived validity and enforceability challenges. The principal result was contractual and commercial: the parties controlled the conditions under which Crystal could pursue approval and potential market entry.

The settlement terms, including any authorized launch date, may not all be publicly available. A dismissal alone does not reveal whether the agreement granted a license, delayed entry until a specified date, included restrictions on launch, or contained ancillary commercial provisions.

Did the case involve biosimilar risk?

No. Entresto is a small-molecule drug, and Crystal’s application proceeded under the ANDA framework. Biosimilar litigation under the Biologics Price Competition and Innovation Act was not applicable.

The relevant competitive threats were:

• ANDA approval after patent and regulatory barriers;
• authorized generic or licensed generic entry;
• other Paragraph IV challengers;
• patent settlements with competing applicants; and
• post-approval competition among multiple sacubitril/valsartan manufacturers.

How strong was Novartis’ Entresto patent estate?

Novartis had a layered estate rather than reliance on a single patent. The portfolio included early combination patents and later patents that could extend coverage across formulations, uses, and product-specific features.

Strength factor	Assessment
Product importance	High; Entresto was a major Novartis growth product
Composition coverage	Strongest potential infringement theory where the generic copied the active combination
Formulation coverage	Dependent on Crystal’s tablet and manufacturing specifications
Method-of-use coverage	Dependent on the proposed label and induced-infringement evidence
Patent layering	Substantial, with multiple issued patents
Invalidity exposure	Relevant because overlapping patents may face written-description, obviousness, enablement, or anticipation attacks
Settlement leverage	Increased by the 30-month stay and commercial value of delayed entry
Precedential value of Crystal case	Limited because there was no reported merits judgment

The estate’s practical strength was greater than a simple patent count suggests. Multiple patents can increase settlement leverage, but overlapping claims may also create validity and obviousness vulnerabilities. The most durable protection usually comes from claims that read directly on the approved product rather than claims dependent on a particular indication or prescribing behavior.

What was the commercial impact of potential generic entry?

Entresto became one of Novartis’ largest products. Novartis reported Entresto sales of approximately $6.0 billion in 2023, making U.S. generic-entry timing financially material.[5]

A generic launch could affect:

1. U.S. net sales and gross margin;
2. payer contracting and rebate levels;
3. market share in heart failure with reduced ejection fraction;
4. prescribing behavior by cardiologists and primary-care physicians;
5. licensing economics for Crystal and other ANDA applicants; and
6. valuation of Novartis’ cardiovascular franchise.

The impact would depend on the number of approved generics, launch sequencing, whether an authorized generic entered, and the scope of any settlement restrictions. A single licensed entrant typically produces less immediate price erosion than several simultaneous generic launches.

What generic launch risks remain after the case closed?

The Crystal case did not eliminate all Entresto patent or commercial risk. Generic-entry analysis must account for:

• the exact settlement launch date, if publicly disclosed;
• remaining Orange Book patents;
• other ANDA applicants and their settlements;
• FDA approval timing;
• potential at-risk launch decisions;
• appellate or district-court rulings in related cases;
• whether any patent is delisted or expires earlier than expected; and
• competition from other sacubitril/valsartan manufacturers in non-U.S. markets.

Geographic coverage also differs. A Delaware ANDA case addresses U.S. patent rights only. It does not determine European, Canadian, Japanese, Chinese, or other national patent rights. Crystal’s Chinese corporate domicile did not change the territorial nature of the U.S. infringement claims.

Key Takeaways

• Novartis v. Crystal, Case No. 1:21-cv-01452-RGA, was an Entresto ANDA Paragraph IV case in the District of Delaware.
• Crystal challenged Novartis patents covering sacubitril/valsartan compositions, formulations, and related uses.
• The case did not involve a biosimilar or biologic.
• The docket does not show a reported merits trial or final judgment on patent validity or infringement.
• The dispute ended through a negotiated disposition, limiting its precedential value.
• Entresto’s effective U.S. exclusivity required analysis of Orange Book listings, patent-term adjustments or extensions, pediatric exclusivity, and later-issued patents.
• Entresto’s multibillion-dollar annual sales made generic-entry timing commercially significant.
• The case’s outcome should be analyzed together with other Entresto ANDA litigation and any public settlement terms.

FAQs About Novartis v. Crystal Pharmaceutical

What product did Crystal seek to copy?

Crystal sought approval for a generic version of Entresto, the sacubitril/valsartan fixed-dose combination marketed by Novartis.

Was Novartis v. Crystal a patent-infringement trial?

No reported merits trial or final patent-validity judgment appears in the public docket. The case ended through a negotiated resolution.

Did Crystal’s lawsuit involve a 30-month FDA stay?

The Paragraph IV litigation framework generally triggered the Hatch-Waxman 30-month stay after Novartis filed suit within the statutory period. The precise operation of the stay depended on the ANDA certifications and later procedural events.

Can Crystal launch immediately after dismissal?

Not necessarily. Dismissal does not itself establish FDA approval, patent clearance, or an unrestricted launch right. Any launch timing would depend on the settlement, remaining patents, FDA action, and other legal barriers.

Does the Delaware case affect Entresto patents outside the United States?

No. The case concerned U.S. patent rights and U.S. FDA approval. Foreign patent rights and regulatory approvals require separate analysis.

References

1. U.S. District Court for the District of Delaware. (2021). Novartis Pharmaceuticals Corporation v. Crystal Pharmaceutical (Suzhou) Co., Ltd., No. 1:21-cv-01452-RGA. PACER docket.
2. U.S. Food and Drug Administration. (2024). Entresto prescribing information. FDA.
3. Federal Food, Drug, and Cosmetic Act, 21 U.S.C. § 355(j).
4. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book. FDA.
5. Novartis AG. (2024). Annual report 2023. Novartis.